14–3-3 η ETA protein as a potential marker of joint damage in gout
Clinical Biochemistry, cilt.118, 2023 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 118
- Basım Tarihi: 2023
- Doi Numarası: 10.1016/j.clinbiochem.2023.110611
- Dergi Adı: Clinical Biochemistry
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
- Anahtar Kelimeler: 14–3-3 η protein, Gout, Matrix metalloproteinases, İnterleukin 1β
- Ankara Yıldırım Beyazıt Üniversitesi Adresli: Evet
Özet
Introduction: The aim of the study is to investigate serum levels of 14–3-3 η (ETA) protein in patients with gout and possible relations with joint damage. Method: This cross-sectional study included 43 gout patients and 30 control patients. Results: Serum 14–3-3 η protein levels were significantly higher in gout patients (median [IQR], 3.1 [2.0] vs 2.2 [1.0], p = 0.007). In subgroup analyses of gout patients, serum 14–3-3 η protein levels did not differ between patients with and without a flare, tophaceous disease, elevated CRP and serum uric acid levels and a history of chronic kidney disease; however, were significantly higher in the patients with erosions (Median [IQR], 4.1 [2.7] vs 2.7 [1.5], p = 0.002). According to ROC curve, serum 14–3-3 η protein had 86.0% sensitivity and 30% specifity at a cut-off point of 1.7 ng/mL and had 74.7% sensitivity and 43.3% specifity at a cut-off point of 2.0 ng/mL. Conclusion: Our results demonstrated elevated levels of 14–3-3 η protein in gout patients which is more prominent in patients with erosive changes, implying role of 14–3-3 η protein in inflammatory and structural damage related pathways and suggesting a potential as a marker for disease severity.